Literature DB >> 32920932

An approach for the transition from systemic immunosuppressants to dupilumab.

L E M de Wijs1, J P Thyssen2, C Vestergaard3, H B Thio1, A C M Kunkeler1, T Biedermann4, D J Hijnen1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32920932     DOI： 10.1111/jdv.16941

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN： 0926-9959            Impact factor:   6.166


× No keyword cloud information.
  1 in total

1.  One-Year Effectiveness and Safety of Dupilumab Treatment for Moderate-to-Severe Atopic Dermatitis in Korean Patients: A Real-World Retrospective Analysis.

Authors:  Hanjae Lee; Bo Ri Kim; Kyu Han Kim; Dong Hun Lee; Jung Im Na
Journal:  Allergy Asthma Immunol Res       Date:  2022-01       Impact factor: 5.764
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.